Brokerages Anticipate Edesa Biotech, Inc. (NASDAQ:EDSA) to Announce -$0.37 EPS

Analysts expect that Edesa Biotech, Inc. (NASDAQ:EDSAGet Rating) will report earnings of ($0.37) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Edesa Biotech’s earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.41). Edesa Biotech reported earnings per share of ($0.19) in the same quarter last year, which would indicate a negative year over year growth rate of 94.7%. The company is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Edesa Biotech will report full year earnings of ($1.33) per share for the current fiscal year, with EPS estimates ranging from ($1.57) to ($1.15). For the next fiscal year, analysts forecast that the company will report earnings of $0.97 per share, with EPS estimates ranging from ($1.42) to $5.26. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Edesa Biotech.

Edesa Biotech (NASDAQ:EDSAGet Rating) last announced its quarterly earnings results on Monday, February 14th. The company reported ($0.33) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.07.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Verition Fund Management LLC acquired a new position in Edesa Biotech during the 3rd quarter worth about $100,000. Geode Capital Management LLC lifted its stake in Edesa Biotech by 4.3% during the 3rd quarter. Geode Capital Management LLC now owns 77,249 shares of the company’s stock worth $570,000 after acquiring an additional 3,217 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Edesa Biotech by 220.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 49,870 shares of the company’s stock worth $281,000 after acquiring an additional 34,306 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Edesa Biotech during the 4th quarter worth about $186,000. Finally, State Street Corp lifted its stake in Edesa Biotech by 64.9% during the 4th quarter. State Street Corp now owns 22,875 shares of the company’s stock worth $129,000 after acquiring an additional 9,000 shares in the last quarter. 2.70% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Edesa Biotech stock traded up $0.04 during trading hours on Monday, hitting $2.22. The company’s stock had a trading volume of 50,441 shares, compared to its average volume of 59,085. The firm has a fifty day moving average of $3.02 and a 200-day moving average of $4.89. Edesa Biotech has a twelve month low of $2.07 and a twelve month high of $12.00.

About Edesa Biotech (Get Rating)

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis.

Read More

Get a free copy of the Zacks research report on Edesa Biotech (EDSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.